Pharmacogenomics of antimicrobial agents
Ar Kar Aung1, David W Haas, Todd Hulgan
1Department of General Medicine & Infectious Diseases, The Alfred Hospital, Melbourne, Victoria, Australia.
Pharmacogenomics
|December 16, 2014
Summary
Genetic factors significantly impact how individuals respond to antimicrobial drugs, affecting both treatment effectiveness and potential side effects. Understanding these pharmacogenomic influences is crucial for personalized medicine and preventing adverse drug reactions.
Area of Science:
- Pharmacogenomics
- Infectious Diseases
- Clinical Pharmacology
Background:
- Individual variability in antimicrobial drug efficacy and toxicity is influenced by numerous factors.
- Genetic variations in drug-metabolizing enzymes can alter antimicrobial pharmacokinetics and pharmacodynamics.
- Human Leukocyte Antigen (HLA) genes are associated with severe immune-mediated adverse drug reactions.
Purpose of the Study:
- To review recent advancements in antimicrobial pharmacogenomics.
- To explore how these genetic factors influence antimicrobial treatment efficacy and toxicity.
- To discuss challenges in translating pharmacogenomic discoveries into clinical practice.
Main Methods:
- Literature review of recent studies in antimicrobial pharmacogenomics.
- Analysis of genetic factors affecting drug metabolism and immune responses.
- Examination of case studies demonstrating clinical translation, such as HLA-B*57:01 screening.
Main Results:
- Pharmacogenomic factors, including genetic variants and HLA types, play a significant role in antimicrobial drug response.
- Advances in understanding these factors have led to successful clinical applications, like preventing abacavir hypersensitivity.
- The field has evolved considerably over the past two decades.
Conclusions:
- Pharmacogenomic insights are essential for optimizing antimicrobial therapy and minimizing toxicity.
- Bridging the gap between pharmacogenomic discovery and routine clinical implementation remains a key challenge.
- Personalized antimicrobial treatment strategies hold significant promise for improved patient outcomes.
More Related Videos
Related Concept Videos
01:27Pharmacogenetics of Drug Metabolism: Overview
170
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
170
01:29Pharmacogenetics and Pharmacogenomics: Overview
214
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
214
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
135
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
135
01:27Principles of Pharmacogenetics: Types of Genetic Variants
121
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
121
01:29Pharmacogenomics: Identification of New Drug Targets
104
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
104
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
286
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
286